• Oxaliplatin br Acknowledgment Supported in part by NIH R EB

  2024-11-19

  

  Acknowledgment Supported in part by NIH1R21EB012707 (Biegon, Anat PI). Introduction Estrogens exert pleiotropic effects on a variety of morphological, physiological and behavioral responses in all vertebrate classes ranging from fishes to mammals. Effects of estrogens in the Oxaliplatin conc

• br Acknowledgments br Introduction Cancer is a deadly

  2024-11-19

  

  Acknowledgments Introduction Cancer is a deadly disease of uncontrolled cell division and has the potential to invade or spread to other parts of the body and affects normal functioning of the vital organs. Nowadays cancer is considered as leading cause of human death in all over the world and

• The increased occurrence of ARIA E in

  2024-11-18

  

  The increased occurrence of ARIA-E in APOE ε4 carriers in phase 2 studies resulted in separate protocols for carriers and noncarriers in the subsequent phase 3 studies. Two 18-month trials comprising 1121 carriers and 1331 noncarriers with mild to moderate AD tested doses of bapineuzumab that varied

• 1 646 There is a growing body of evidence showing that pento

  2024-11-18

  

  There is a growing body of evidence showing that pentobarbital causes memory disorders [3], [4], [5]. Our results that a single injection of pentobarbital into bilateral hippocampus significantly impaired hippocampus-dependent spatial memory retrieval (Fig. 1) add support to that evidence. Previous

• br Polymorphic variation ERAP is polymorphic

  2024-11-18

  

  Polymorphic variation ERAP1 is polymorphic and several single nucleotide polymorphisms (SNPs) in its gene that encode amino IMD 0354 receptor changes have been associated with predisposition to a variety of diseases, ranging from viral infections to cancer and autoimmunity (Alvarez-Navarro and L

• br Alzheimer s disease AD

  2024-11-18

  

  Alzheimer’s disease (AD) is an irreversible, age-associated neurodegenerative disorder that is characterized by progressive memory loss and cognitive decline. AD is also the leading cause of dementia, accounting for 5 million cases in the United States and 44 million cases worldwide. In 2015, AD c

• Recently two distinct small molecule

  2024-11-18

  

  Recently, two distinct small-molecule inhibitors of PHGDH were identified using high-throughput screens, both of which inhibit de novo serine biosynthesis and show selective toxicity to cancer glucokinase with high SSP flux [50,51]. The inhibitor NCT-503, which has an IC50 of 2.5μM, reduces the gro

• Atypically BcALDH has a minor

  2024-11-18

  

  Atypically, BcALDH has a minor reducing activity for all-trans-retinal, which requires the binding of the reduced form of the NADP+ (NADPH) cofactor that is a side-product of the canonical oxidation activity of BcALDH. The reduction activity that converts all-trans-retinal to all-trans-retinol was r

• Exposure to B a P

  2024-11-18

  

  Exposure to B[a]P is an epidemiologically proven cause of lung cancer (Hecht, 2003; Rojas et al., 2004; Alexandrov et al., 2010), and the formation of B[a]PDE-N2-dG adducts is considered to be the critical event in lung tumorigenesis by B[a]P. On the other hand, there is evidence suggesting that the

• br Functions essentially consisting in transport

  2024-11-18

  

  Functions essentially consisting in transport of substrates across plasma membranes Direct activation of neurotransmitter transporters elicits responses in neurons As previously mentioned (Section 2.1), nerve terminals handling classical transmitters possess transporters able to (re)capture se

• Vortioxetine is a multimodal antidepressant that acts as an

  2024-11-18

  

  Vortioxetine is a multimodal antidepressant that acts as an inhibitor at the serotonin (5-HT) transporter (SERT), an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors, and an antagonist at 5-HT1D, 5-HT3 and 5-HT7 receptors (Bang-Andersen et al., 2011, Sanchez et al., 2015). Based on

• The obtained results indicate that even

  2024-11-18

  

  The obtained results indicate that even when the impairment of the same forms of memory are present, amnesia can develop in different ways. Impairment of memory reconsolidation in the conditioned food aversion model through both the serotonin receptor antagonist and the antagonist of NMDA glutamate

• br Materials and methods br Results br Discussion

  2024-11-18

  

  Materials and methods Results Discussion More experiments were performed in order to explain the mechanism that is involved in jnk inhibitor death both PC3 and Hep G2 cells using compound 5. Results showed that this compound inhibits cell viability inducing apoptosis in a concentration-dep

• In summary we could identify

  2024-11-18

  

  In summary, we could identify and experimentally confirm two novel SBEs within the 5-LO promoter and we were able to demonstrate that TGFβ and SMADs stimulate 5-LO promoter activity. Moreover, an elevated 5-LO expression has been linked to different forms of leukaemia. Therefore, the influence of ML

• These results from the present study are summarized in Table

  2024-11-18

  

  These results from the present study are summarized in Table 1. Eight drugs (doxorubicin, epirubicin, daunorubicin, idarubicin, irinotecan, imatinib, sunitinib and gefitinib) inhibited 5-HT-induced 5-HT3A and 5-HT3AB currents; three (irinotecan, topotecan and mitoxantrone) showed different responses

16011 records 50/1068 page Previous Next First page 上5页 4647484950 下5页 Last page